Wendy A. Woodward, MD, PhD
The EORTC 22922 trial reported a significant reduction in breast cancer mortality and recurrence in patients with stage I to III disease, but also underscored the need for a predictive assay to qualify who will benefit the most from regional node irradiation, said Wendy A. Woodward, MD, PhD.
State of the Science Summit™ on Breast Cancer, Woodward, professor and chief, Clinical Breast Radiotherapy Service, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, highlighted encouraging advances and ongoing developments with radiotherapy in breast cancer.
OncLive: What are some of the most important trials in radiotherapy for breast cancer that recently read out?
The most important radiotherapy trial that was presented at the 2018 ASCO Annual Meeting was EORTC 22922. This was a randomized trial of regional nodal irradiation. It was for stage I to III patients who were node positive and had central or medial tumors. The primary endpoint was OS; the secondary endpoints were all of the other typical tumor outcomes.
... to read the full story